Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancer

BJU Int. 2023 Feb;131(2):179-182. doi: 10.1111/bju.15930. Epub 2022 Nov 30.

Richard Kelly^{1

2}, Andrew Jensen³, Nathasha Karunaratna⁴, Shirley Wong⁵, Julia Shapiro⁶, Andrew Weickhardt⁷, Phillip Parente^{4

8}, Arun A Azad², Anthony Uccellini⁷, Javier Torres⁹, Francis Parnis^{10

11}, Jeffrey Goh^{12

13}, Edmond M Kwan¹⁴, Stephen Brown¹⁵, Christopher Steer¹⁶, Mark Warren¹⁷, Peter Gibbs^{1

5}, Ben Tran^{1

2

3}, Angelyn Anton^{1

4

8}

¹ Walter and Eliza Hall Institute of Medical Research, Melbourne, Vic., Australia.
² Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
³ Epworth Health, Melbourne, Vic., Australia.
⁴ Eastern Health, Melbourne, Vic., Australia.
⁵ Western Health, Melbourne, Vic., Australia.
⁶ Alfred Health, Melbourne, Vic., Australia.
⁷ Olivia Newton-John Cancer Wellness and Research Centre, Melbourne, Vic., Australia.
⁸ Monash University, Melbourne, Vic., Australia.
⁹ Goulburn Valley Health, Shepparton, Vic., Australia.
¹⁰ Adelaide Cancer Centre, Adelaide, SA, Australia.
¹¹ University of Adelaide, Adelaide, SA, Australia.
¹² Royal Brisbane and Women's Hospital, Herston, Qld, Australia.
¹³ University of Queensland, Brisbane, Qld, Australia.
¹⁴ Monash Health, Melbourne, Vic., Australia.
¹⁵ Ballarat Health, Ballarat, Vic., Australia.
¹⁶ Border Medical Oncology, Albury, NSW, Australia.
¹⁷ Bendigo Health, Bendigo, Vic., Australia.

No abstract available

Publication types